Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Washington for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Washington only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Washington (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Srivalli Gopaluni (NPI 1427208990)

Field	Value
Entity Type	Individual
Organization	Srivalli Gopaluni
Address	605 E Holland Ave
City	Spokane
State	WA
ZIP	99218
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	September 22, 2008

Payer Source	Total Paid
Medicare	$1.6M
Medicaid	$0

Key Findings

This provider is an infusion-focused hematology/oncology practice where high-cost immunotherapy agents drive revenue: J9271 (pembrolizumab) and J9299 (nivolumab) together generate $670.8K and $454.2K respectively, representing the two largest single-code revenue sources on the Medicare file. The precomputed share shows the top 3 Medicare codes account for 77.8% of this provider's total Medicare revenue, underscoring a business model heavily weighted toward drug administration over ancillary services.

Revenue concentration is pronounced and centered on a few biologics and supportive oncology drugs: J9271 accounts for $670.8K (42.3% of total Medicare revenue), J9299 accounts for $454.2K (28.7%), and J0897 (denosumab) adds $108K (6.8%). Because these three codes compose 77.8% of Medicare revenue, the provider’s financial performance is sensitive to utilization and reimbursement changes for these specific agents.

Payer mix is effectively single-payer Medicare: the provider reports Total Medicare revenue of $1.6M and has no Medicaid billing on file. This absence of Medicaid activity means analytics and competitive benchmarking should focus on Medicare dynamics and national peer comparisons rather than state Medicaid markets.

Operationally, the coding mix (large volumes of J9271 and J9299 plus sizable counts of chemotherapy administration and add-on codes such as 96413 and 96417) indicates a practice that delivers both immunotherapy and intravenous chemotherapy on-site. Procedure and infusion codes like 96413 (656 claims) and 96417 (300 claims) appear alongside supportive agents such as J2506 (408 claims), suggesting integrated infusion services with on-site drug handling and supportive care workflows.

Competitive standing on the national Medicare table is mixed: for primary revenue drivers, J9271 ranks #640 of 1841 providers nationally (65th percentile; typical, unremarkable volume) and J9299 ranks #170 of 505 providers nationally (66th percentile; typical, unremarkable volume), so the practice is a modest participant for these immunotherapies rather than a national leader. By contrast, several administration and E/M codes show notably higher relative activity — for example, 99214 ranks #17647 of 479517 (96th percentile; notably above typical national volume) and 96413 ranks #319 of 7514 (96th percentile; notably above typical national volume) — indicating stronger-than-typical service delivery intensity around visits and chemo infusions.

Several codes are statistical outliers relative to national peers on utilization intensity: 96417 ranks #62 of 3014 providers (98th percentile; notably above typical national volume), 96375 ranks #115 of 5191 (98th percentile; notably above typical national volume), and 96411 ranks #64 of 1354 (95th percentile; notably above typical national volume). These high-percentile add-on and infusion codes point to above-typical throughput in multi-drug infusion sessions and sequential drug administration compared with peers.

The provider’s mix shows higher revenue contribution from drug administration than from evaluation-and-management: combined high-dollar drug codes (J9271 and J9299) account for the majority of Medicare dollars, whereas top E/M codes such as 99214 ($81.1K, 836 claims) and 99215 ($40.6K, 296 claims) contribute much smaller shares of total revenue. This pattern is consistent with a practice whose financial footprint is dominated by oncology drug delivery rather than office visit billings.

Tenure is established: the NPI was enumerated 2008-09-22 (~18 years ago), indicating long-standing Medicaid-free Medicare participation and likely continuity in local referral networks and infusion operations. Given the provider’s long enrollment and concentrated Medicare revenue base, payers and analysts should prioritize monitoring reimbursement shifts for pembrolizumab and nivolumab as the primary drivers of revenue volatility.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

50 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	15,600	$40	$670.8K
J9299	Injection, nivolumab, 1 mg	19,750	$20	$454.2K
J0897	Injection, denosumab, 1 mg	6,000	$20	$108K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	840	$100	$81.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	660	$110	$68.9K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	300	$140	$40.6K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	410	$100	$38.8K
96417	In this add–on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report administration of a different chemotherapy…	300	$50	$15.6K
96375	Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the…	1,150	$10	$13.8K
96521	The provider refills a portable pump with a chemotherapy drug.	110	$100	$10.7K

Showing 1–10 of 50

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 50 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Washington Distribution

Srivalli Gopaluni — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Washington

Full comparison — all codes billed, vs. state median

50 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	4	30	9,600	$40	$465.7K
J9299	3	10	17,740	$20	$404.3K
J0897	19	150	1,800	$20	$57.9K
J3490	8	70	70	$50	$51.2K
J2506	2	10	360	$80	$28.2K
96413	4	160	80	$110	$15K
99214	200	10,860	100	$80	$13.6K
99233	1,156	2,420	60	$90	$10.4K
J0185	3	10	6,630	$1	$10.2K
99215	143	4,320	40	$120	$8.4K

Showing 1–10 of 50

Related Providers

Other providers that share a Tax Identification Number (TIN) with Srivalli Gopaluni, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
St. Joseph Hospital LLC	ID	General Acute Care Hospital	$0	$4.7M
Cancer Care Northwest Centers P S	WA	Hematology & Oncology Physician	$0	$3M
Danko Martincic	ID	Hematology & Oncology Physician	$2.6M	$0
Columbia Surgical Specialists, Ps	WA	Ambulatory Surgical Clinic/Center	$891.1K	$1.2M
Vijay Narendran	FL	Hematology & Oncology Physician	$2M	$0
Saritha Thumma	WA	Hematology & Oncology Physician	$1.8M	$0
Hakan Kaya	WA	Medical Oncology Physician	$1.8M	$0
Christopher Lee	WA	Radiation Oncology Physician	$1.7M	$0
Elizabeth Gunderson	WA	Medical Oncology Physician	$1.6M	$0
Wayne Lamoreaux	WA	Radiation Oncology Physician	$1.5M	$0

Nearby Providers

Other providers in the same ZIP code as Srivalli Gopaluni, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Toillion Pediatric Dentistry	WA	Pediatric Dentistry	$0	$17.6M
Multicare Health System	WA	Family Medicine Physician	$0	$13.5M
Mt. Spokane Pediatrics, PLLC	WA	Multi-Specialty Clinic/Center	$0	$12.4M
Nora Laughlin	WA	Registered Nurse	$0	$9.2M
Kirk Fuhriman PLLC	WA	Dentist	$0	$7.5M
Advanced Lifeline Services Inc	WA	Certified Respiratory Therapist	$0	$7.4M
Mobile Anesthesia For Children	WA	Dental Clinic/Center	$0	$5.5M
The Kidds Place, Dentistry For Children, P.s.	WA	General Practice Dentistry	$0	$4.8M
Inland Northwest Renal Care Group, LLC	WA	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$3M
Brenen Swofford	WA	Hematology & Oncology Physician	$1.2M	$0

Srivalli Gopaluni — Billing Profile & Reimbursement Data

Sign up for Srivalli Gopaluni — Billing Profile & Reimbursement Data policy alerts

Srivalli Gopaluni — Billing Profile & Reimbursement Data

Sign up for Srivalli Gopaluni — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References